These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23539537)

  • 21. Expression studies of missense mutations p.D141Y, p.C275S located in the propeptide of von Willebrand factor in patients with type 3 von Willebrand disease.
    Baronciani L; Federici AB; Cozzi G; La Marca S; Punzo M; Rubini V; Canciani MT; Mannucci PM
    Haemophilia; 2008 May; 14(3):549-55. PubMed ID: 18328061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homozygous type 2N R854W von Willebrand factor is poorly secreted and causes a severe von Willebrand disease phenotype.
    Castaman G; Giacomelli SH; Jacobi P; Obser T; Budde U; Rodeghiero F; Haberichter SL; Schneppenheim R
    J Thromb Haemost; 2010 Sep; 8(9):2011-6. PubMed ID: 20586924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor.
    Ribba AN; Hilbert L; Lavergne JM; Fressinaud E; Boyer-Neumann C; Ternisien C; Juhan-Vague I; Goudemand J; Girma J; Mazurier C; Meyer D
    Blood; 2001 Feb; 97(4):952-9. PubMed ID: 11159522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
    Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
    Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defective dimerization of von Willebrand factor subunits due to a Cys-> Arg mutation in type IID von Willebrand disease.
    Schneppenheim R; Brassard J; Krey S; Budde U; Kunicki TJ; Holmberg L; Ware J; Ruggeri ZM
    Proc Natl Acad Sci U S A; 1996 Apr; 93(8):3581-6. PubMed ID: 8622978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variable content of von Willebrand factor mutant monomer drives the phenotypic variability in a family with von Willebrand disease.
    Chen J; Hinckley JD; Haberichter S; Jacobi P; Montgomery R; Flood VH; Wong R; Interlandi G; Chung DW; López JA; Di Paola J
    Blood; 2015 Jul; 126(2):262-9. PubMed ID: 26019279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins.
    Bodó I; Katsumi A; Tuley EA; Eikenboom JC; Dong Z; Sadler JE
    Blood; 2001 Nov; 98(10):2973-9. PubMed ID: 11698279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
    Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms.
    Cartwright A; Webster SJ; de Jong A; Dirven RJ; Bloomer LDS; Al-Buhairan AM; Budde U; Halldén C; Habart D; Goudemand J; Peake IR; Eikenboom JCJ; Goodeve AC; Hampshire DJ
    Blood Adv; 2020 Jul; 4(13):2979-2990. PubMed ID: 32609846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VWF-Gly2752Ser, a novel non-cysteine substitution variant in the CK domain, exhibits severe secretory impairment by hampering C-terminal dimer formation.
    Okamoto S; Tamura S; Sanda N; Odaira K; Hayakawa Y; Mukaide M; Suzuki A; Kanematsu T; Hayakawa F; Katsumi A; Kiyoi H; Kojima T; Matsushita T; Suzuki N
    J Thromb Haemost; 2022 Aug; 20(8):1784-1796. PubMed ID: 35491445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients.
    Yadegari H; Driesen J; Pavlova A; Biswas A; Hertfelder HJ; Oldenburg J
    Thromb Haemost; 2012 Oct; 108(4):662-71. PubMed ID: 22871923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study.
    Eikenboom J; Hilbert L; Ribba AS; Hommais A; Habart D; Messenger S; Al-Buhairan A; Guilliatt A; Lester W; Mazurier C; Meyer D; Fressinaud E; Budde U; Will K; Schneppenheim R; Obser T; Marggraf O; Eckert E; Castaman G; Rodeghiero F; Federici AB; Batlle J; Goudemand J; Ingerslev J; Lethagen S; Hill F; Peake I; Goodeve A
    J Thromb Haemost; 2009 Aug; 7(8):1304-12. PubMed ID: 19566550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular genetics of von Willebrand disease.
    Mazurier C; Ribba AS; Gaucher C; Meyer D
    Ann Genet; 1998; 41(1):34-43. PubMed ID: 9599650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of intracellular storage and regulated secretion of 3 von Willebrand disease-causing variants of von Willebrand factor.
    Michaux G; Hewlett LJ; Messenger SL; Goodeve AC; Peake IR; Daly ME; Cutler DF
    Blood; 2003 Oct; 102(7):2452-8. PubMed ID: 12791651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease.
    Baronciani L; Federici AB; Cozzi G; Canciani MT; Mannucci PM
    J Thromb Haemost; 2007 Feb; 5(2):282-8. PubMed ID: 17155947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding and multimerization.
    Schneppenheim R; Lenk H; Obser T; Oldenburg J; Oyen F; Schneppenheim S; Schwaab R; Will K; Budde U
    Thromb Haemost; 2004 Jul; 92(1):36-41. PubMed ID: 15213842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor.
    Riddell AF; Gomez K; Millar CM; Mellars G; Gill S; Brown SA; Sutherland M; Laffan MA; McKinnon TA
    Blood; 2009 Oct; 114(16):3489-96. PubMed ID: 19687512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function.
    Meyer D; Fressinaud E; Hilbert L; Ribba AS; Lavergne JM; Mazurier C
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):349-64. PubMed ID: 11686104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.